gallium-68-dotatate (netspot) Report issue

Small molecule Imaging Orphan Drug FDA Approved FDA Priority Review FDA
AACT ChEMBL Drug Central Drugs@FDA MeSH PubChem

Active Ingredient History

NOW
  • Now
Dotatate gallium (Ga-68) (Ga-DOTATATE ) under the brand name NETSPOT is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients. In addition, was shown, that Ga-DOTATATE can be used for detection the incidental medullary thyroid carcinoma. It binds to cells that express somatostatin receptors including malignant cells, which overexpress somatostatin subtype 2 receptors.   NCATS

Chemistry

  • SMILES: [68Ga+3].CC(O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN3CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC3)C(=O)N[C@@H](CC4=CC=C(O)C=C4)C(=O)N[C@H](CC5=CNC6=C5C=CC=C6)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O
  • InChIKey: XBJPSVQFCQFGDC-WSCOIBMGSA-K
  • Mol. Mass: 1500.527
  • ALogP: Missing data
  • ChEMBL Molecules:
    gallium dotatate ga-68  
    edotreotide gallium ga-68  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Imaging: 68-gallium
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Alternative names

(68ga-dota-3-iodo-tyr(3),thr(8))octreotide | 68ga-dota-iodo-tyr(3)-octreotate | 68ga dotatate | 68ga-dotatate | (68ga)gallium dotatate | 68ga-ha-dotatate | 68gallium-dota-tyr(3)-thr(8)-octreotate | dotatate gallium ga-68 | edotreotide gallium ga-68 | ga-68 dota0-tyr3-octreotide | ga-68 dotatoc | ga-dotatate | gallium 68 dota-octreotide | gallium 68 dotatate | gallium-68-dotatate | gallium (68ga) dota-tate | gallium (68ga) edotreotide | gallium-dota-octreotate, ga-68 | gallium dotatate ga-68 | gallium dotatate, ga-68 | gallium edotreotide ga-68 | gallium ga 68 dotatate | gallium ga 68-dotatoc | gallium ga 68-edotreotide | gallium ga-68 edotreotide | netspot

Organizations (30)

Research & Development (28)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (33)

Approved Indications (1)


 

Neuroendocrine Tumors (approved 2016)

Experimental Indications - Clinical Trial Phases 1-4 (33)


 

Adenoma, Islet Cell (Phase 1/Phase 2)

Adrenocorticotropic Hormone (Phase 2)

Apudoma (Phase 1/Phase 2)

Breast Neoplasms (Phase 1)

Carcinoid Tumor (Phase 1/Phase 2)

Carcinoma, Hepatocellular (Phase 1/Phase 2)

Carcinoma, Neuroendocrine (Phase 2)

Coronary Artery Disease (Phase 3)

Cushing Syndrome (Phase 2)

Diagnostic Imaging (Phase 2)

Diagnostic Techniques and Procedures (Phase 2)

Ganglioneuroblastoma (Early Phase 1)

Ganglioneuroma (Early Phase 1)

Glioblastoma (Phase 1)

Heart Diseases (Phase 4)

Hypercalcemia (Phase 2)

Hyperparathyroidism (Phase 2)

Meningioma (Phase 2)

Multiple Endocrine Neoplasia (Phase 2)

Multiple Endocrine Neoplasia Type 1 (Phase 2)

Neoplasms (Phase 1)

Neuroblastoma (Phase 2)

Neuroendocrine Tumors (Phase 2)

Osteomalacia (Phase 1/Phase 2)

Pancreatic Neoplasms (Phase 2)

Paraganglioma (Phase 2)

Parathyroid Neoplasms (Phase 2)

Pheochromocytoma (Phase 2)

Prostatic Neoplasms (Phase 2)

Prostatic Neoplasms, Castration-Resistant (Phase 2)

Small Cell Lung Carcinoma (Phase 1)

Thyroid Neoplasms (Phase 2)

von Hippel-Lindau Disease (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 34
  • # of Trial Organizations: 28

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue